Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) said Friday that a monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to the already approved drug Dupixent.